For example, modelling
based on the figures in this paper suggests that
ACEI/ARB prescribing for patients with hypertension
400 and proteinuria produces a mean annual net saving to the
NHS of ∼£470 per treated patient over a 5-year perspective.
This saving arises through reduced ESRD, stroke and
MI risk [29, 30]. QOF data indicate that, in 2009–10, 82
834 people with hypertension and proteinuria (6.1% of
405 those who had an ACR or PCR test) were treated with
ACEIs/ARBs. The net annual saving for this group, over
a 5-year perspective, is estimated at £39 million